Aclaris Therapeutics (ACRS) EBIT (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly EBIT of -$22.2 million for Q1 2026, down 22.72% year-over-year from -$28.7 million in Q1 2025, and up 2.38% quarter-over-quarter from -$22.7 million in Q4 2025.
Aclaris Therapeutics (ACRS) EBIT (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' EBIT history runs 13 years deep, the most recent figure standing at -$22.2 million for Q1 2026.
- In Q1 2026, EBIT fell 22.72% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$80.5 million (up 42.95% YoY), while the FY2025 annual figure was -$76.4 million, up 46.19% from the prior year.
- EBIT for Q1 2026 stood at -$22.2 million, up from -$22.7 million in the prior quarter.
- The five-year high for EBIT was -$4.0 million in Q4 2023, with the low at -$99.7 million in Q4 2024.
- The 5-year median for EBIT is -$20.9 million (2022), against an average of -$25.2 million.
- The sharpest annual moves came in 2023 and 2024: EBIT surged 86.08% in 2023, then plunged 2362.94% in 2024.
- Aclaris Therapeutics' EBIT stood at -$29.1 million in 2022, then soared by 86.08% to -$4.0 million in 2023, then slumped by 2362.94% to -$99.7 million in 2024, then surged by 77.19% to -$22.7 million in 2025, then advanced by 2.38% to -$22.2 million in 2026.
- Business Quant data shows ACRS's EBIT at -$22.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$17.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -24.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.24 Mn |
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -22.73 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Jun 30, 2025 | -18.41 Mn |
| Mar 31, 2025 | -18.08 Mn |
| Dec 31, 2024 | -99.68 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.85 Mn |
| Mar 31, 2024 | -18.93 Mn |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | -31.58 Mn |
| Jun 30, 2023 | -31.82 Mn |
| Mar 31, 2023 | -29.92 Mn |
| Dec 31, 2022 | -29.08 Mn |
| Sep 30, 2022 | -20.87 Mn |
| Jun 30, 2022 | -20.99 Mn |
| Mar 31, 2022 | -18.91 Mn |
| Dec 31, 2021 | -22.89 Mn |
| Sep 30, 2021 | -20.30 Mn |